Takeki Uehara | Corporate Officer, Senior Vice President, Drug Development and Regulatory Science Division
Shionogi & Co., Ltd

Takeki Uehara, Corporate Officer, Senior Vice President, Drug Development and Regulatory Science Division, Shionogi & Co., Ltd

Dr. Takeki Uehara received his DVM degree at the Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Japan, in 2002. After his graduation, he joined Shionogi & Co., Ltd. as a research scientist. In 2008 he received his PhD degree of Veterinary Medicine granted by Osaka Prefecture University. His current position is Corporate Officer, Senior Vice President, Drug Development and Regulatory Science Division and serves as a global project leader for an anti-influenza agent, baloxavir marboxil (Xofluza) and anti-COVID-19, S-217622 in Shionogi & Co., Ltd. He published over 70 peer reviewed papers. He has served as an organizer of international workshops, educational courses in several international conferences, a reviewer for scientific journals and editorial board in the scientific journals.

Appearances:



Day 2 - November 29 @ 12:20

Ensitrelvir - an Oral 3CL Protease Inhibitor for the treatment of COVID-19

last published: 02/Jan/24 12:15 GMT

back to speakers